## **GPC KEY POPULATION COMMUNITY OF PRACTICE WEBINAR | 4 April 2023**

Measuring & monitoring the Key Population programme outputs & outcomes at national and global level

### POPULATIONS CLÉS DU GPC COMMUNAUTÉ DE PRATIQUE WEBINAR | 4 Avril 2023

Mesurer et suivre les réalisations et les résultats du programme pour les populations clés aux niveaux national et mondial







### HOUSEKEEPING

X

### SESSION DETAILS

	Measuring and monitoring the Key Population Programite – 4 <sup>th</sup> April 2023	mme outputs and outcom	es at National and Global
Meeting of	chair: Tim Sladden and Clemens Benedikt	11:00 - 12:30 (CEST)	16:00 - 17:30 (CEST)
Time	Session	Facilitators / Speakers	Facilitators / Speakers
5 min	Opening remarks Welcome Objectives of the meeting	Tim Sladden	Clemens Benedikt
25 min	Global Overview: This will include sharing of the 2025 global targets in relation to key population programme and reflections around approaches to measure outputs and outcomes for Key Population programmes		
	Investment in robust monitoring and evaluation systems including available evidence to plan and improve programmes including funding requests	Keith Sabin, UNAIDS Amrita Rao, JHU Kate Rucinski, JHU	Keith Sabin, UNAIDS Amrita Rao, JHU Kate Rucinski, JHU
	Need for programme data triangulation to improve programming and overview of the new monitoring and evaluation toolkit developed by UNAIDS		
2.5 min	Priority (interactive) Why would you prioritize monitoring and evaluating Key Population programmes in your country?	Mentimeter	Mentimeter
25 min	Practical approaches to implementing a monitoring and evaluation system to monitor progress of KP programme Country presenters will share how the specific country has developed practical strategies led by the government to measure and monitor KP programmes.	Keshab Deuba and Neeti Sedhain, Nepal Dr. Peter Mudioppe, Uganda	Dr. Jebet Boit, Kenya Dr. Ketevan Stvilia, Georgia
25 min	Programmatic Key Population Community Led Monitoring (CLM) approach and practices Presenter(s) from KP-led organisations and networks will share their successful efforts and practices in leading community led monitoring processes	Shahnaz, Tais Plus Viet Trinh, Light House	Aniedi Akpan, DHRAN Sean Regg, Transbantu
2.5 min	Reflections (interactive) What is the most important action you will take to strengthen the monitoring and evaluation of key population programme in your country?	Mentimeter	Mentimeter
5 min	Closure Summary of actions and next steps	Tim Sladden	Clemens Benedikt
	·	r	

# X

### **OBJECTIVES**

- Create a safe space for frank discussion how to accelerate programmes
- Facilitate peer-to-peer/country-to-country exchange of experiences in programme development, implementation, monitoring, evaluation and community engagement;
- Receive updates on global policy, latest guidance, implementation tools and financing opportunities

# **OPENING REMARKS**

### Clemens Benedikt

# **GLOBAL OVERVIEW**

Keith Sabin, UNAIDS Amrita Rao, JHU Kate Rucinski, JHU




# ENDING AIDS BY 2030

## **KEITH SABIN**


### Ending AIDS by 2030: it cannot happen unless we prioritize key populations

Keith Sabin, UNAIDS Data for Impact practice



8


### **Global Ambitions**



Public Health approach Targets: can we achieve without some groups? => utilitarian approach


<u>Rights approach</u> Targets: Apply to <u>all</u> possible groups? => Equity approach

### Number of new HIV infections, global, 1990–2021, and 2025 target




Source: UNAIDS epidemiological estimates, 2022 (https://aidsinfo.unaids.org/).

### Number of AIDS-related deaths, global, 1990–2021, and 2025 target




Source: UNAIDS epidemiological estimates, 2022 (https://aidsinfo.unaids.org/).

### Distribution of acquisition of HIV infection by population, global, 2021



Number of new HIV infections. The number of new HIV infections per 1,000 uninfected population, by sex, age and <u>key populations</u> as defined as the number of new HIV infections per 1000 person-years among the uninfected population.

# Distribution of acquisition of new HIV infections by population, global, sub-Saharan Africa and rest of the world, 2021




REMAINING POPULATION

Source: UNAIDS special analysis, 2022 (see Annex on Methods).

Note: Due to variations in the availability of data from one year to the next, we do not provide trends in this distribution. See Annex on Methods for a description of the calculation.


### Relative risk of acquisition of HIV infection by population, global, 2021



Risk compared to remaining population of same gender identity


UNAIDS special analysis, 2022

# Percentage change in HIV incidence among key populations, global, 2010–2019



Source: UNAIDS special analysis of available key population data, 2020.

# Gap between country-reported key population size estimates and extrapolated sizes, global, 2020



### **Targets thresholds for 2025**

	Criterion	Very high	High	Moderate and low
Sex workers	National adult (15-49 years) HIV prevalence	>3%	>0.3%	<0.3%
Prisoners	National adult (15-49 years) HIV prevalence	>10%	>1%	<1%
Gay men and other men who have sex with men	UNAIDS analysis by country/region	Proportion of populations estimated to have incidence >3%	Proportion of populations estimated to have incidence 0.3–3%	Proportion of populations estimated to have incidence <0.3%
Transgender people	Mirrors gay men and other men who have sex with men in absence of data	Proportion of populations estimated to have incidence >3%	Proportion of populations estimated to have incidence 0.3–3%	Proportion of populations estimated to have incidence <0.3%
People who inject drugs	UNAIDS analysis by country/region	Low needle–syringe programme and opioid substitution therapy coverage	Some needle–syringe programme; some opioid substitution therapy	High needle-syringe programme coverage with adequate needles and syringes per person who injects drugs; opioid substitution therapy available

### **Targets for 2025**

KEY POPULATIONS	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners and others in closed settings
Condoms/lubricant use at last sex by those not taking PrEP with a non-regular partner whose HIV viral load status is not known to be undetectable (includes those who are known to be HIV-negative)		95%	95%	95%	
Condom/lubricant use at last sex with a client or non-regular partner	90%				90%
PrEP use (by risk category) Very high High Moderate and low	80% 15% 0%	50% 15% 0%	15% 5% 0%	50% 15% 0%	15% 5% 0%

### Estimates of HIV-free key populations for ≈160 countries


Country	WB_Class	Max Estimated Med Risk	Est Med risk as % of PSE	Est High risk	Min Estimated High risk	Max Estimated High risk	Est high risk as % of PSE
Ghana	Lower middle income	28592	21%	71559	59761	82506	61%
Guinea	Low income	1162	57%	479	393	609	28%
Guinea-Bissau	Low income	5211	55%	3263	2627	3938	<mark>4</mark> 1%
Haiti	Low income	45171	58%	17 <mark>1</mark> 11	14094	22075	25%

### **Translating Coverage Targets to Numbers: 2025**


Population	Population Size (Millions)	Coverage Target	Target (Millions)
FSW	11.9	9.4%	1.1
MSM	30.0	14.0%	4.2
Transgender	5.3	15.8%	0.8
PWID	12.3	5.3%	0.6
Prisoners	10.4	1.4%	0.1
AGYW	532	0.1%	0.4
ABYM	571	0.02%	0.1
Adults 25+ with multiple partners	163	0.3%	0.5
Total	1336	0.6%	8.0

\*Coverage target is weighted average across all countries and population risk groups.

Number of people who received pre-exposure prophylaxis (PrEP) at least once during the reporting period, by region, 2017–2021




Number of people who received pre-exposure prophylaxis (PrEP) at least once during the reporting period, by region, 2021, and 2025 target



Source: UNAIDS Global AIDS Monitoring, 2022 (https://aidsinfounaids.org/).

# Gap to achieve the combination prevention targets among key populations, by intervention and region, 2017–2021

#### EASTERN AND SOUTHERN AFRICA



Source: UNAIDS Global AIDS Monitoring, 2022 (https://aidsinfo.unaids.org/); UNAIDS special analysis, 2022

Note: "HIV prevention programmes coverage" refers to the key populations that reported receiving at least two prevention services in the past three months. Possible prevention services received included: condoms and lubricant and counselling on condom use and safer sex (all key populations); testing for sexually transmitted infections (sex workers, transgender people and gay men and other men who have sex with men; and sterile injecting equipment (people who inject drugs).

## USE OF ROUTINE DATA TO ANSWER PROGRAM-RELEVANT QUESTIONS

### KATE RUCINSKI & AMRITA RAO



# X

### OUTLINE

#### Routinely collected program data

- What is routinely collected data?
- Challenges and opportunities
- Developing questions of impact

#### Example analyses using program data

- Patterns of PrEP use among FSW and AGYW in South Africa
- 2. Impact of implementation strategies on PrEP persistence among FSW and AGYW in South Africa
- 3. Extrapolation of population size estimates for FSW and MSM in Namibia



### **ROUTINELY COLLECTED DATA**




### Routinely collected data (Nicholls et al. 2018)


- Data collected for purposes other than research or without specific research questions developed prior to collection
- These data can support 1) clinical management of patients or service users, and/or 2) monitoring and evaluation of program activities


### **Examples**


- Clinical information from health records
- Health administrative data (e.g. claims or receipts of payment)
- Program registers
- Epidemiologic Surveillance Systems















### Using program data: challenges and opportunities



### Challenges

- Often incomplete or messy
- Challenging to access and obtain individual-level data
- Difficulty linking individuals over time (switching to different clinics, moved out of the area)
- Competing priorities to data collection

#### **Opportunities**

- Data from real-world setting
- Already being collected, so does not involve additional person power or data collection costs
- Can help in studying much larger groups of people
- Answer questions that would otherwise be unething too expensive to study

### **Development of questions of impact: a partnership**

- Create research-practice partnerships or develop research capacity in-house
- Questions developed should be responsive to program needs and gaps in knowledge
  - Demand for services
  - Available resources
  - o Implementation
  - o Identification of hotspots (geographic, by population group, etc.)
- Continuous feedback from on the ground service providers about findings and adaptation



- Add rigor in evaluation of existing systems
- Answer program-relevant questions, while improving and strengthening systems
  - How data are captured
  - How data are **managed**
  - How data are **used**





#### CASE STUDY EXAMPLES USING PROGRAM DATA



# 01

## Examine patterns of PrEP initiation, discontinuation, re-initiation, and cycling among FSW and AGYW who initiated PrEP in South Africa



#### **Research – practice partnership**




#### **TB HIV Care and Johns Hopkins University**

- Longstanding research-practice partnership between TB HIV Care and JHU
- Data were reviewed together and questions were developed to be responsive to program needs and gaps in knowledge
- Adding methodologic rigor to the evaluation and understanding of existing systems





#### **Study population**



Female sex workers and adolescent girls and young women receiving prevention services through TB HIV Care

Women would have been eligible if they were accessing other prevention services (testing for pregnancy or STIs; family planning) and were HIV negative

Multiple TB HIV Care Sites across 6 provinces




FSW: June 2016 - August 2021


AGYW: May 2018 - September 2020



**01)** Examine patterns of PrEP initiation, discontinuation, re-initiation, and cycling among FSW and AGYW who initiated PrEP




#### **01)** Examine patterns of PrEP initiation, discontinuation, re-initiation, and cycling among FSW and AGYW who initiated PrEP



# **01)** Examine patterns of PrEP initiation, discontinuation, re-initiation, and cycling among FSW and AGYW who initiated PrEP









## Evaluate the impact of implementation strategies on PrEP persistence among FSW and AGYW served by TB HIV Care

#### **PrEP** persistence at one month

Whether or not a client returned to pick up her PrEP refill at one-month following initiation

Data at the individual level were **aggregated to produce monthly site-specific counts** of the number of women who picked up their 1-month PrEP refills and counts of the number of women who initiated PrEP in the prior month (who would be expected to pick up a PrEP refill)

# **02)** Evaluate the impact of implementation strategies on PrEP persistence among FSW and AGYW served by TB HIV Care



 WhatsApp support groups: groups of PrEP users where members can discuss successes and challenges in using PrEP





- **Clinical mentoring for providers**: weekly meetings conducted with PrEP providers, led by a nurse clinician or clinical trainer to review best practices for PrEP provision
- **Mobile van PrEP provision**: decentralized delivery of PrEP in the community using a TB HIV Care mobile van



- SMS PrEP refill reminder: text messages sent one week before and one day before scheduled refill
- Generic SMS support: text messages of support sent once a week designed to empower and promote self efficacy
- **Loyalty rewards program:** incentives in the form of airtime (credit used to make calls, send texts, or access the internet) for initiating and returning for PrEP visits
- **Case management approach**: Nurse clinicians and assigned case managers provide dedicated follow-up of PrEP users to support and guide with HIV prevention care

We evaluated the independent impact of...


- Đ C
- **1)** clinical mentoring for providers
- 2) SMS refill reminders and support texts
- 3) case management approach, and



4) loyalty rewards program

#### $Y_{t} = \beta_{0} + \beta_{1}T + \beta_{2}X_{1} + \beta_{3}X_{2} + \beta_{4}X_{3} + \beta_{5}X_{4} + \beta_{6}(COVID) + offset(person\ time)$

Where X1 represents clinical mentoring for providers, X2 represents SMS PrEP refill reminders and support texts, X3 represents the case management approach, and X4 represents the loyalty rewards program



Shaded region represents a pause in the Loyalty Rewards Program



Introduction of **clinical mentoring for providers** was associated with a **12%** increase in 1-month persistence (95% CI: 1.03, 1.23).



Introduction of **SMS support and refill reminders** was associated with a **33%** increase in 1-month persistence (95% CI: 1.18, 1.50).



Introduction of **the case management approach** was not associated with any increase in 1-month persistence (95% CI: 0.92, 1.13).



Introduction of **the loyalty rewards program** was associated with a **26%** decrease in 1-month persistence (95% CI: 0.67, 0.82).




# Extrapolation of population size estimates for FSW and MSM in Namibia



## **03)** A lack of reliable population size estimates (PSE) for key populations contributes to gaps in knowledge across the HIV cascade

- Size estimates are among most volatile, unreliable estimates in HIV public health
- Nonexistent in rural, remote areas and/or settings with most unmet needs
- Small area estimation can help fill in gaps

Program data are typically excluded from small area estimation approaches





## **03)** In Namibia, differences in PSEs exist within and across regions for FSW and MSM

KP	Region	Direct Estimation Method						
		Mapping	Key Informant	Unique Object	Wisdom of the	Literature	Stakeholder	SS-PSE
			Interview	Multiplier	Crowds	Review	Consensus	
FSW	Zambezi	284	300	5299	300	84	800	674
		(142-426)	(50-4300)	(3500-8575)	(100-1000)	(47-251)	(380-2000)	(318-2426)
	Ohangwena	158	100	1494	500	85	900	900
		(79-237)	(30-800)	(1249-1822)	(300-1000)	(47-254)	(775-2750)	(775-2750)
	Erongo	322	330	2352	700	241	900	1057
		(161-483)	(200-1000)	(1597-4557)	(200-2000)	(134-723)	(825-1500)	(576-3369)
	Khomas	528	100	5240	600	1582	3000	2196
		(264-792)	(50-1700)	(3373-11706)	(200-1500)	(1055-2110)	(1800-3400)	(1651-2382)
MSM	Karas	282	1132	1714	100	84	500	-
		(141-423)	(200-2948)	(1292-2359)	(40-400)	(24-138)	(300-650)	
	Oshana	78	2000	3538	150	157	500	-
		(39-117)	(250-5184)	(2379-5632)	(50-500)	(45-259)	(350-800)	
	Erongo	488	100	2982	70	427	610	670
		(244-732)	(70-300)	(2013-5808)	(40-250)	(122-701)	(475-658)	(410-1610)
	Khomas	460	300	2229	400	1207	2416	2210
		(230-690)	(100-1600)	(1699-3240)	(no bounds	(345-1983)	(850-4000)	(382-10410)
					available)			

Table 1. Direct Estimates (2012-2014, 2019), n (95% CI), by Key Population and Region\*

\*Data collected between 2012-2014 and 2019<sup>18,19</sup>

- Quarterly data provided by community-based HIV service providers can approximate the number of individuals engaging with HIV programs
- While imperfect, can cumulatively function as a lower bound for PSEs in districts or regions where services are being provided

How can we systemize the integration of program data in small area estimation approaches?



#### **03)** Triangulating multiple PSEs using prior beliefs via a consensusestimation approach

- Triangulator (formerly Consensus Estimator) developed by Dr. Ian Fellows et al. (<u>https://epiapps.com/shiny/app\_direct/shinyprox</u> y combine\_estimates/)
- Leverages known information about the distribution of each population to inform a singular estimate for each region
- Weights each direct estimate based on userdefined confidence (e.g., multiplier methods may be more rigorous than wisdom of the crowd methods)

#### EPIAPPS

#### THE TRIANGULATOR

The Triangulator is a Shiny user interface designed to help derive consensus estimates of a population quantity (e.g. a population size, a proportion, a mean, etc.) from multiple empirical estimates. Stakeholders may add additional information regarding the methodological quality of the studies and prior knowledge of the metric. Triangulated estimates are statistically defensible, reproducible and openly inspectable.

LAUNCH APPLICATION

Authors: Ian E. Fellows and Carl Corcoran

Github: https://github.com/fellstat/triangulator



## **03)** Weighting PSEs based on quality of study implementation and prior beliefs

- PSE methods ranked by level of confidence (0-100)
- Internal "tests" explored varying levels of confidence to calculate triangulated PSEs for each region
- Prior beliefs for the distribution of the derived size estimates were defined based on quarterly program data

	ce				
Method	Test 1	Test 2	Test 3		
Mapping	75	75	85		
Key Informant Interview	55	60	65		
Unique Object Multiplier	85	85	95		
Wisdom of the Crowd	40	40	50		
Literature Review	60	60	70		
Stakeholder Consensus	65	60	75		
SS-PSE	90	90	99.9		
	<b>Results from Consensus Estimator Tool</b>				
	Test 1	Test 2	Test 3		
Median (SD)	429.29 (90.91)	425.34 (92.66)	367.62 (66.58)		

Supplemental Table 1. Example Determination of Confidence Values, FSW in Zambezi



#### **03)** Changes in extrapolated PSE proportions after including program data

Table 2. Absolute and Proportion Estimate Differences in FSW Extrapolated Estimates Before and After the Integration of Programmatic Data

	Simple Imputation		Stratified Imp Prevalence	utation, HIV	Stratified Imputation, Population Density	
Stratified Imputation	Pre-	Post-	Pre-	Post-	Pre-	Post-
	Programmatic	Programmatic	Programmatic	Programmatic	Programmatic	Programmatic
	Data	Data	Data	Data	Data	Data
	Proportion	Proportion	Proportion	Proportion	Proportion	Proportion
Greater than Median			0.026	0.040	0.011	0.034
Less than/Equal to Median	0.019	0.028	0.014	0.012	0.028	0.010


**FSW** 

Table 3. Absolute and Proportion Estimate Differences in MSM Extrapolated Estimates Before and After the Integration of Programmatic Data


	Simple Imput:		Stratified Imputation, HIV Prevalence		Stratified Imputation, Population Density	
If Stratified Imputation	Pre-	Post-	Pre-	Post-	Pre-	Post-
-	Programmatic	Programmatic	Programmatic	Programmatic	Programmatic	Programmatic
	Data	Data	Data	Data	Data	Data
	Proportion	Proportion	Proportion	Proportion	Proportion	Proportion
Greater than Median			0.021	0.008	0.014	0.0045
Less than/Equal to Median	0.015	0.0075	0.013	0.007	0.015	0.010

**MSM** 

Extrapolated national estimates ranged from 4777 to 13148, comprising 1.5% to 3.6% of women ages 15-49



Extrapolated national estimates ranged from 4611 to 10171, comprising 0.7%-1.5% of men ages 15-49



- Using SAE approaches, we combined epidemiologic and program data to generate subnational size estimates for key populations in Namibia
- The inclusion of program data increased the proportion of FSW in high-density/high HIV prevalence regions and decreased the proportion of MSM in all regions
- Future work is needed to determine how best to include program data in KP size estimation studies, ultimately bridging research with practice to support a more comprehensive HIV response.





#### DISCUSSION

•••••••••••••••••••••••••••••••••••••••



#### **Program data present an opportunity for:**

Collaboration

• Repurposing existing data and analyses and infusing additional methodologic rigor

• Shedding light on program-relevant questions





#### WITH THANKS

#### **Questions?**

Kate Rucinski rucinski@jhu.edu Amrita Rao arao24@jhu.edu















Mentimeter



PRACTICAL APPROACHES TO IMPLEMENTING A MONITORING & EVALUATION SYSTE TO MONITOR PROGRESS OF KP PROGRAMME

Dr Jebet Boit, Kenya Dr Ketevan Stvilia, Ekaterine Ruadze and Maka Gogia, Georgia




PRACTICAL APPROACHES TO IMPLEMENTING A MONITORING AND EVALUATION SYSTEM TO MONITOR PROGRESS OF KP PROGRAM

## DR JEBET BOIT



#### The Key Population Program: at a Glance

- Led by Ministry of Health (MOH) NASCOP and NSDCC since 2008, provides strategic direction, technical support and coordination, and evidence; sets standards; mobilises resources, and establishes an enabling environment
- Technical Support Unit implemented by UoM established to support scale-up of interventions in 2012
- Funding through MOH, PEPFAR, GFATM, and other funders to 95 implementing partners (IPs) in 37/47 counties
- MOH leadership instills confidence in IPs to implement a prevention programme for KPs, though sex work, same sex relationship and drug possession and use are criminalized in Kenya










#### **Role of Key Populations in Kenya**

- Kenya Modes of Transmission study (2008) identified key populations as groups disproportionately affected by HIV, contributing to 33% of all new infections. However, the current national data shows a reduction to 13%.
- IBBS results (2010), showed a higher burden of HIV among key populations, prevalence 3–5 times higher than the general population

Current data illustration










#### Data Sources in the Kenya KP Programme








#### Mapping and Size estimation


- Mapping and size estimation conducted in 2012 and repeated in 2018-2020. Virtual mapping conducted in 2019 to estimate the population size of MSM who meet partners in virtual spaces.
- Used the data to determine denominators and targets and develop a scale up plan.
- Used the evidence to develop guidelines to reach the unreached like virtual MSM, young key populations








## **Routine program monitoring – development of national tools**





#### Mapping of Implementing Partners

• NASCOP mapped all the KP implementing partners in the country in 2012

#### **Development of Reporting Tools**

- Developed a set of KP reporting tools in 2014 partnership with
  - Members of key populations
  - Donor agencies
  - Implementing partners
  - Tools were revised in 2018

#### Output

- 22 data collection tools
- Monthly and quarterly tools
- High reporting since 2014





#### **Routine Program Monitoring – capacity strengthening**



#### **Series of Trainings Conducted**

- Definition of indicators and variables
- Responsibility of various staff cadres in tool completion
- Periodicity of filling the tools


## **Quality of Reporting Checked**

- Desk review on receipt of reports
- Regular RDQA
- Analysis and sharing of data to the IPs and County and national managers
- Presentation of data in TWG and COE





## **Routine Monitoring: Unique Identifier Code**



Source: UIC guidance note, NASCOP







#### **Routine monitoring - One National Reporting System**

#### **Reporting through Kenya Health**

#### Information System (KHIS) – MOH 731plus



#### Data Management: Kenya Electronic Medical Record System (Kenya EMR)








#### Routine monitoring - One National Reporting System

- All implementing partners (421 reporting unit) enter the KP program performance data on a monthly basis using MOH 731plus form
- The filled form is submitted to the county CHRIO who enter the data into the KHIS
- The data is analysed at county and national level to monitor program progress and performance
- Implementers who use the EMR system for data entry can automatically generate the reports using MOH 731 plus





#### **Analysis and Information Use:** Hotspot Levels to IP level to sub national and national level by sub population




Implementing Partner-level analysis: color coded based





#### Routine Monitoring System: National Reporting and Feedback Framework








#### Outcome measurement

- The national program conduct IBBS to measure outcomes. IBBS was conducted in 2010-11. The 2nd one will take place in 2023.
- The KP program also conducts annual surveys to measure outcomes using Polling Booth Survey Methods
- This data is used to understand programme outcomes like condom use, PrEP use or prevalence of violence at the population level
- Monitoring data and survey data is used to develop prevention and treatment cascades at subpopulation and county levels to understand programme gaps and develop strategies to address the gaps





#### **Coordination and Management**



- At the national level, a M&E sub-committee has been formed to coordinate the monitoring and evaluation issues.
- Chaired by NASCOP, member representation is drawn from:
  - Donor agencies
  - Members of key populations
  - Implementing partners
  - The Sub Committee reports to the national KP TWG
  - The sub committee supports technical decisions related to reporting tools and guidelines, analysis of data, development of protocols etc.






## PILOTING OF THE BBS-LITE AMONG PWID IN GEORGIA, 2021-2022

KETEVAN STVILIA EKATERINE RUADZE MAKA GOGIA

#### Georgia

- Population 3,7 M
- Estimated number of PWID: 52,500 (=2% of adult population)
- Georgia is located on important route of drug traffic from Afghanistan and Central Asia to Europe



The first BSS was conducted in 2007 in Georgia The last BSS before BSS Lite was conducted in 2017-2018

International donors' support is decreasing in EECA region

State allocations covers critical diagnostic and treatment services, but not research Simplified, quality and affordable methodologies have to be developed To test the feasibility of the methodology and protocol

- To measure HIV and HCV prevalence among PWID
- To assess HIV risk behaviour
- To measure access to HIV testing, prevention, and treatment services among PWID
- To generate evidence for advocacy, policy-making and programming

#### **Comparison of IBBS & BSS-Lite methodologies**

<b>BSS-Lite (2021)</b>	Standard IBBS (2022)
 2000	2005
6 weeks	12 weeks
The same 7 major cities	The same 7 major cities
Harm reduction service providers	Non-service providers
<ul> <li>Consecutive recruitment at NSP sites &amp; mobile outreach</li> <li>Snowball recruitment (3-5 coupons)</li> </ul>	<ul> <li>Respondent driven sampling (3 coupons)</li> </ul>
37 questions (focus on core indicators)	182 questions (+10 questions for network size)
<ul> <li>Questionnaire on tablet devices + paper</li> <li>Administered by trusted VCT consultants and outreach workers at office &amp; during mobile outreach</li> </ul>	<ul> <li>Paper based questionnaire</li> <li>Administered by external interviewers</li> </ul>
<20 minutes	> 45 min
USD 75,000	USD192,300

90

#### Study cycle

Both on HR sites and in Mobile Ambulatories trained personnel could conduct RDT and collect samples for RNA testing As HR sites are the implementing organizations of the State HIV Program they were able to use RDTs procured through the State Program – cost saving

HR staff has collected 15 digit unique identifier codes from the participants and they were reported as covered with HIV testing through the state program – **Achieving testing targets and getting additional income for the organization**  Short questionnaire – less time required for the analysis and report writing

Data analyses

Selection of service sites

In the regions (6 sites) regular BSS also using the same HR sites

> Training of service site staff

> > NSP site personnel had **experience of conducting PDI** (peer driven intervention) and it was easy to train them on BSS Lite steps





Enrollment time 5-6 weeks instead of 4 weeks (due to COVID 19 new wave) On some days there was a large surge of participants, staff had to stay after working hours, but as they were incentivized, they didn't complain

Field work at harm reduction sites and through mobile ambulatories

Development of online database and dashboard

Refusal rate was <5% as the most of participants knew and trusted the study team

Study **steps were not much different from the standard** NSP service provision except of the questionnaire, but it was made short

#### **Electronic database and online dashboard**

**Online entry for questionnaire** - <u>https://www.veed.io/view/5561c110-fe4e-4676-8f73-688ba8996b0e?aspect-ratio/Landscape&category=Media</u>


**Online monitoring** - Quality of data entry; Control over the progress of the Study

BBS <sub>ම</sub>					E 🔒					
<ul> <li>ලංශුය</li> <li>මომხმარებლები (15 &gt;</li> </ul>	ბოლოს შევსებულ	ი ფორმები			ყველა ფორმის ჩანირა					
	# ნომერი	ასაკი	სქესი	მოქმედეზა	BBS	۲				E (
	27	18 Feol	მამროზითი	± /	ரு மல		32 23 (	ელის მამრობითი	± /	
	30	35 წლის	ტრანსგენდერი	± 🖌	💿 მომხმარებლებ	n <b>15</b> >				
	31	18 Feol	მამრობითი	± /			გიჩვენებთ 1 დან 2 ჩათვლით 2 შედე	გიდან		წინა 📘 შემდეგი
	32	წლის42	მამრობითი	± /			ანალიტიკა			
	33	წლის53	მამრობითი	± 🖌			303000033			
	34	415ლის	მამრობითი	± 🖌			2	1	1	0
	35	წლის30	მამრობითი	± 🖌			სულ შვსებული ფორმა	ბოლო 24 საათის განმავლობაში შევსებული ფორმა	აუთრიჩიდან	სერვის ცენტრიდან
	36	წლის63	მამრობითი	± /						
									<b>O</b> კუპონით ,,თოვლის გუნდის" მეთოდით	1 ახალი კლიენტი 🛛 😂

#### **Recruitment methods for BSS Lite**

All Study participants (N=2000) Service Center, (29%) Snowball, (47%) Mobile outreach, (24%)

#### New Clients of NSP (N=658, 33% of all participants)



#### **Comparison of BSS-Lite & IBBS (2022) results**

		IBBS (2022)		
	Clients (N=658)	Non-clients (N=1,342)	Total (N=2,000)	Total (N=2005)
Client of harm reduction service*	-	-	67.1%	60.4%
Participated in 2021 BBS-lite	-	-	-	4.0%
Median age	44 years	39 years	43 years	44 years
Female	2.6%	2.6%	2.6%	1.4%
Drug last injected:				
Heroin/Sirets	29.5%	27.9%	28.5%	30.1%
Methadone/Subutex/Suboxone	63.8%	60.6%	62.9%	54.1%
Amphetamine/Methamphetamine	7.3%	5.5%	6.7%	5.6%
Overdose in the last 12 months	7.7%	5.0%	6.8%	10.1%
Used sterile needle-syringe last injection	83.4%	77.7%	81.5%	78.7%**
Condom use during last sex	48.4%	34.5%	39.6%	38.7%

\* For BBS-lite defined as those participants who were registered clients of harm reduction service
 For IBBS defined as those who reported having received needles-syringes from NSP in last 12 months
 \*\* People who never re-used injection equipment

#### Comparison of BSS-Lite & IBBS (2022) results

		IBBS (2022)		
	Clients (N=658)	Non-clients (N=1,342)	Total (N=2,000)	Total (N=2005)
Received needles-syringes from NSP in last 3 months	86.7%	3.2%	59%	60.4%
Received OAMT in last 12 months	67.3%	56.5%	64.3%	21.7%
Tested for HIV in the last 12 months	60.9%	36.3%	69.3%	37.5%
HIV positive	1.4%	1.2%	1.4%	0.9%
HIV positive who knew status	100% (19/19)	87.5%*(7/8)	96.2%*	98%
HIV positive on ART	100% (19/19)	75%* (6/8)	92.5%*	Not available
Anti-HCV positive	63.8%	41.6%	56.5%	58.1%
HCV RNA positive	14.7%	14.7%	14.7%	24.1%

\* One individual Refused to answer

#### Lessons learned from BSS-Lite pilot (1)

#### Simple in implementation

Requires considerably less time for recruitment, data collection, data analysis and interpretation (less work burden) Flexibility to interview clients at service centres and during outreach Regular BSS is administered at study sites only

# Saves time, costs, and other resources

Questionnaire shorter and takes less time to complete compared to the regular BSS questionnaire – time is especially critical when interviewing PWID Can be implemented at **much lower cost (2.6 – 3.6 times less)** than the regular BSS, thus **more frequently** BBS-Lite \$74,500 (in 2021) Standard IBBS \$192,300 (in 2022) \$270,000 (in 2017)

#### Lessons learned from BSS-Lite pilot (2)

Allows for frequent tracking of PWID for risk behaviour, access and utilization of the harm reduction, testing and treatment services (uses the same indicators as regular BSS for comparison)


Methodology was able to produce data that were useful for programming and decision making

Smart methodology gives other possibilities

Participants felt comfortable with the harm reduction service staff interviewing them and happy with short questionnaire Outreach and snowball allowed recruitment of new, hidden or lost to follow up PWID, who otherwise would not come to harm reduction programs

As samples are collected, they **can be tested on other infections,** we tested for Covid-19, self-reported vaccination coverage was 46%

# Depending on the Testing outcomes participants were linked to HR services, confirmation testing, treatment and care



#### **Use of BSS-Lite Results for Program/service planning**

Information was generated on types of drugs injected and injection frequency	<ul> <li>Helps to tailor harm reduction counseling to the needs of the community</li> <li>To improve planning of centralized procurement of injecting equipment</li> </ul>
<ul> <li>★ Prevalent unprotected sex (&gt;60%) among PWID</li> <li>★17.3% reported re-using own syringes</li> </ul>	relevant updates were introduced in the risk reduction counselling instruction for outreach workers to improve safe sex counselling/promote condom use and reduce re-use of own syringes
65.4% of PWID reported using naloxone distributed by the program to prevent overdose related death	<ul> <li>Important evidence is provided in support of distribution of naloxone through the Needle and Syringe Program</li> </ul>
≈ 60% PWID uses both, NSP&OAMT services	<ul> <li>Discussion was initiated to integrate NSP in OAMT or place new vending machines for distribution of injecting equipment near to OAMT clinics</li> </ul>
>80% of PWID reported getting clean syringes from pharmacies	<ul> <li>Place more vending machines at pharmacies, or come up with a new effective intervention that can be integrated in pharmacy chains</li> </ul>

#### Trust and data ownership

Community Trust	<ul> <li>Trust is especially important for PWID community we can assume that PWID's responses were more honest to the questions asked by the NSP staff</li> </ul>
Trusting the results	<ul> <li>Communities have greater trust in the results of studies conducted by the community organizations</li> </ul>
Data Ownership	<ul> <li>Communities learning how to use research data to modify services, to use research as catalytic tool, think of potential future research questions</li> </ul>



#### **THANK YOU!**

You can reach us at:

stviliak@gmail.com e.ruadze@ncdc.ge and marine\_gogia@yahoo.com













## COMMUNITY LED MONITORING OF THE NEEDLE AND SYRINGE PROGRAM FOR PEOPLE WHO INJECT DRUGS IN NIGERIA

## **ANIEDIAKPAN**



## BACKGROUND

# PURPOSE OF CLM 2

#### STEPS TO DEVELOPING FRAMEWORK 3

#### IMPLEMENTION LEVELS

4

# ADVOCACY USING CLM DATA 5

#### CHALLENGES

6

### IMPROVING CLM

X

#### CONTENT



- Funded by the Global Fund (GF) through the Community Rights and Gender Strategic Initiative (CRG SI)
- Led by the Drug User Network (DHRAN)
- Used to Monitor the GF-funded Needle and Syringe program (NSP) in the 3 Pilot States
- Monitoring targeted at Community and Facility Level
- Indicators developed by Community Members

- Monitor quality of NSP service provision.
- Monitor access of community members (People who Inject Drugs) to the services
- Monitor acceptability of the NSP service
- Monitor compliance with NSP implementation standard
- Monitor stock-outs of commodities
- Serves to understand community needs

DEVELOPING CLM FRAMEWORK	07:37 ⓑ ◀ ⊘ • kc.kobotoolbox.org	
	Fill Blank Form	
<ul> <li>Meeting with Drug User community leaders to define Indicators</li> </ul>	Edit Saved Form	
	Send Finalized Form	
<ul> <li>Contracting of Consultant to develop CLM Framework and refining Indicators</li> </ul>	View Sent Form (54)	
<ul> <li>Review of Framework/Indicators by Community leaders</li> </ul>	Get Blank Form	
Coding on online data callection platformer	Delete Saved Form	
<ul> <li>Coding on online data collection platforms</li> </ul>	KoboCollect v2022.4.4	
<ul> <li>Training of data collectors</li> </ul>		

• Piloting of CLM/Review/Implementation of CLM

 $\Box$ 

0

 $\triangleleft$ 

#### **IMPLEMENTATION LEVELS**

- 1. Facility Level
  - a. Data Collected: Quantitative data
  - b. Mode of collection: Interview
- 2. Community Level
  - a. Data Collected:
    - i. Quantitative data
    - ii. Qualitative Data
  - b. Mode of Collection:
    - i. Interview
    - ii. 5 Focal Group discussions (10 persons/FGD)

07:37 🖹 🖪 🖉 • 👘	07:38 🖲 ◀ 🔗 🔸	÷ •
CLIENT/COMMUNITY QUANTITAT	FACILITY QUANTIT	<b>N.</b> :
	* A. STATE O GOMBE	
	0 0Y0	
Rights Awareness and Experience		
Group		
Stockout of drugs and commodities		
Name of Data Collector		
Designation		
Phone number		
Record your current location		
Go To Start Go To End		NEXT >
	0 0 1	

#### **ADVOCACY USING CLM DATA**

Advocacy and dissemination of CLM reports exists at:

- 1. Technical Working Groups periodic meetings
- 2. Coordination Meetings
- 3. Global fund country implementing partners structure (PR & SR)
- 4. Visitation to relevant institution





- 1. Resistance by facilities to CLM
- 2. Limited understanding of Indicators for development of questionnaire.
- 3. Limited knowledge of data analysis among community-led organizations
- 4. Limited funding for community-led data collection
- 5. Perceived conflict of interest from community-led organizations leading community-led Monitoring.
- 6. Disagreement of stakeholders on report of CLM



- 1. Improvement of capacity of Key Populations on CLM
- 2. Institution of CLM as an integral part of program implementation for KPs.
- 3. Establishment of advocacy platforms for real time resolution of issues raised/noticed during CLM
- 4. Improved funding for data collection for CLM
- 5. Advocacy with facilities for acceptance of CLM

# THANK YOU

# REFLECTIONS

•

• •

•••

Mentimeter

## CLOSURE

## **Clemens Benedikt**

•

• •

. . .